Medication-Assisted Treatment in New York

There are many treatment options and multiple paths to recovery for individuals experiencing substance use disorders. Medication-assisted treatment (MAT) is one of the most effective and well-researched approaches available, particularly for people struggling with opioid addiction, alcohol dependence, and tobacco use disorder.

While abstinence-based programs and psychotherapy work well for some people, others need additional support to manage the intense physical cravings and withdrawal symptoms that make early recovery so difficult. MAT provides that support by combining FDA-approved medications with counseling and behavioral therapies, offering a whole-patient approach to addiction treatment that addresses both the physical and psychological dimensions of the disorder.

If you or a loved one is dealing with a substance use disorder and looking for an evidence-based treatment plan, understanding how medication-assisted treatment works can help you make an informed decision about the path to a successful, lasting recovery.

What Is Medication-Assisted Treatment (MAT)?

Medication-assisted treatment (MAT) is the use of FDA-approved medications in combination with behavioral therapies, counseling, and psychosocial supports to treat substance use disorders. Rather than relying on a single intervention, MAT takes a whole-patient approach that’s tailored to meet each individual’s unique needs.

The medications used in MAT are approved by the Food and Drug Administration (FDA) for the treatment of opioid use disorder (OUD), alcohol use disorder, and tobacco use disorder. Decades of clinical research have demonstrated that MAT can successfully treat these disorders, sustain long-term recovery, and prevent overdose.

The ultimate goal of MAT is to make full recovery possible so that individuals can live healthy, productive, and independent lives. Research has shown that MAT can:

• Improve patient survival rates and reduce opioid-related overdose deaths
• Increase retention in treatment programs, which is one of the strongest predictors of long-term success
• Decrease illicit opioid use and other illegal activity among people with substance use disorders
• Improve social functioning and increase patients’ ability to gain and maintain employment
• Improve maternal and fetal outcomes for pregnant women with substance use disorders
• Lower a patient’s risk of contracting infectious diseases like HIV or hepatitis C by reducing relapse potential

MAT is recognized by the World Health Organization, which includes both methadone and buprenorphine on its List of Essential Medicines, and by the Substance Abuse and Mental Health Services Administration (SAMHSA) as a frontline treatment for opioid use disorder.

How Does Medication-Assisted Treatment (MAT) Work?

Before starting medication-assisted treatment, a physician, addiction specialist, or qualified healthcare professional will perform a comprehensive assessment to determine the right MAT program for you or your loved one, including the best medications for your needs.

The physician, supported by a medical and psychiatry team, will evaluate your health, history of substance use, any co-occurring mental health conditions, and your treatment goals to develop a customized, individualized treatment plan. They’ll monitor your progress throughout treatment and adjust your prescription or dosage of medication if necessary.

The Role of Medication

MAT medications work by interacting with the same brain circuits and brain chemistry that are affected by addictive substances, but in a controlled, medically supervised way. Depending on the specific medication, they may:

• Normalize brain chemistry that has been disrupted by prolonged substance use
• Block the euphoric effects of opioids or alcohol, reducing the reinforcement that drives continued use
• Relieve physical withdrawal symptoms that make early recovery extremely difficult
• Reduce physical cravings that can persist for weeks or months after stopping substance use

By stabilizing these biological processes, MAT medications give patients the physiological foundation they need to engage meaningfully in therapy, build coping skills, and work toward sustained recovery.

The Treatment Process

The first step in treatment is typically a medical detoxification, during which the patient is safely stabilized and the substance is cleared from their system. Following detox, patients transition into an inpatient or outpatient rehabilitation program where MAT medications are integrated with therapy and counseling.

Treatment initially focuses on stabilization: removing dependence on the substance, managing withdrawal with appropriate medications, and addressing any immediate medical or psychiatric needs. From there, the focus shifts to empowering the patient with healthy coping skills, relapse prevention strategies, and a strong support system to sustain long-term recovery.

How Long Does Medication-Assisted Treatment (MAT) Take?

The duration of MAT varies from person to person. Some individuals benefit from short-term medication use during the early, most vulnerable stages of recovery. Others may need to continue medications for months or even years to maintain stability and prevent relapse.

There is no single “correct” duration for MAT. The length of treatment depends on the severity of the patient’s condition, their response to medication, the presence of co-occurring disorders, and their overall progress in recovery. The need for continued medication is regularly evaluated by the patient’s physician, and treatment plans are adjusted accordingly.

It is important to understand that longer durations of MAT are not a sign of failure. Research consistently shows that patients who remain on MAT medications for adequate periods have significantly better outcomes than those who discontinue prematurely. The decision about when to taper or discontinue medication should always be made collaboratively between the patient and their healthcare provider based on clinical evidence, not external pressure or stigma.

Physicians, nurse practitioners, and medical personnel who provide MAT must complete specialized training to prescribe and administer these medications. MAT can be provided on an outpatient basis as part of a SAMHSA-accredited and certified substance use disorder treatment program, or within inpatient and residential settings for individuals who need a higher level of care.

Therapy and Counseling: Essential Components of MAT

While MAT medications address the physical side of addiction, they are most effective when paired with counseling and behavioral therapy. Medication alone is rarely sufficient for lasting recovery. The combination of pharmacological and behavioral interventions is what makes MAT a comprehensive, whole-patient approach.

Therapy helps patients understand the psychological and emotional dimensions of their addiction, including learning to identify triggers and stressors, developing healthier coping mechanisms, and rebuilding relationships and social functioning. Most MAT programs require patients to engage in therapy alongside medication to ensure they have the full range of tools necessary for sustained recovery.

Behavioral treatments commonly integrated into MAT programs include:

• Cognitive behavioral therapy (CBT): Helps patients identify and change the thought patterns and behaviors that drive substance use. CBT teaches practical skills for managing cravings, avoiding triggers, and responding to high-risk situations without turning to substances.
• Dialectical behavior therapy (DBT): Focuses on building skills in emotional regulation, distress tolerance, interpersonal effectiveness, and mindfulness. DBT is particularly helpful for patients who struggle with intense emotions or co-occurring mood disorders.
• Motivational interviewing (MI): A collaborative, patient-centered approach that helps individuals explore and resolve ambivalence about changing their substance use behavior. MI strengthens internal motivation for recovery rather than imposing change from the outside.
• Addiction counseling: Individual and group counseling sessions that provide ongoing support, accountability, and a safe space to process the challenges of recovery.
• Family therapy: Addiction affects entire families. Family therapy helps repair damaged relationships, improve communication, and educate loved ones about the nature of addiction and the recovery process.
• Peer support groups: Group-based recovery support provides community, accountability, and the opportunity to learn from others who share similar experiences.

The combination of medication and wraparound services, including therapy, counseling, case management, and social support, gives patients the strongest possible foundation for lasting recovery.

FDA-Approved Medications for Opioid Use Disorder

Opioid use disorder (OUD) is a chronic medical condition characterized by persistent cravings for opioids, compulsive use despite negative consequences, and physiological changes in the brain that make stopping extremely difficult without treatment.

OUD can involve dependence on prescription pain relievers such as oxycodone and hydrocodone, semi-synthetic opioids, or illicit substances like heroin. The opioid epidemic has devastated communities across the United States and New York, making access to effective treatment more critical than ever.

There are three primary FDA-approved medications for the treatment of opioid use disorder:

Buprenorphine (Suboxone, Sublocade, Zubsolv)

Buprenorphine is a partial opioid agonist, meaning it activates opioid receptors in the brain but produces a much milder effect than full agonists like heroin, oxycodone, or methadone. This partial activation is enough to reduce cravings and relieve withdrawal symptoms without producing the intense euphoria associated with opioid misuse.

One of buprenorphine’s most significant advantages is that it can be prescribed in office-based settings by qualified physicians, nurse practitioners, and physician assistants, rather than requiring daily visits to a specialized clinic. This dramatically improves treatment access and reduces barriers for patients who might not be able to attend a methadone clinic every day.

Buprenorphine is most commonly prescribed as Suboxone, a combination product that includes both buprenorphine and naloxone. The naloxone component is included as a deterrent against misuse: if the medication is taken as directed (dissolved under the tongue), the naloxone has minimal effect, but if someone attempts to inject the medication, the naloxone activates and can precipitate withdrawal.

Other buprenorphine formulations include Sublocade (a monthly injection) and Zubsolv (sublingual tablets).

Methadone

Methadone is a long-acting full opioid agonist that reduces cravings and prevents withdrawal symptoms by acting on the same opioid receptors as other opioids, but in a controlled, gradual manner that does not produce the rapid onset of euphoria associated with misuse.

Methadone has been used to treat opioid addiction for over 50 years and has one of the longest track records of any addiction medication. It is available as tablets, oral solution, or injectable liquid, but can only be dispensed through SAMHSA-certified opioid treatment programs (OTPs). Patients typically begin by visiting the clinic daily and may earn take-home doses as they demonstrate stability and progress.

Naltrexone (Vivitrol)

Naltrexone is an opioid antagonist that works by completely blocking opioid receptors, preventing opioids from producing any euphoric or sedative effects. Unlike buprenorphine and methadone, naltrexone does not activate opioid receptors at all, which means it carries no risk of physical dependence or diversion.

Naltrexone is available as a daily oral tablet or as Vivitrol, an extended-release naltrexone injection administered once per month. The monthly injection is particularly helpful for patients who have difficulty with daily medication adherence.

An important consideration with naltrexone is that patients must be fully detoxified from opioids before starting treatment. Administering naltrexone to someone who still has opioids in their system can trigger severe, precipitated withdrawal.

Naloxone (Narcan)

While not a treatment medication in the traditional MAT sense, naloxone is a critical, life-saving opioid antagonist that can rapidly reverse an opioid overdose. Naloxone is available as a nasal spray (Narcan) and as an injectable, and it is increasingly being distributed to patients, families, and communities as part of comprehensive opioid treatment programs.

Expanding access to naloxone is a key component of reducing opioid-related overdose deaths. Many MAT programs now include naloxone prescriptions and training as a standard part of treatment, ensuring that patients and their loved ones have the tools to respond to an overdose emergency.

FDA-Approved Medications for Alcohol Use Disorder

Alcohol use disorder is a chronic condition characterized by an inability to control drinking despite negative consequences to health, relationships, and responsibilities. It can range from mild to severe and affects millions of Americans.

Like opioid use disorder, alcohol use disorder is a highly treatable medical condition. Evidence-based treatment programs that combine behavioral therapy with FDA-approved medications give individuals the best chance of achieving and maintaining full recovery.

Three medications are currently approved for the treatment of alcohol use disorder:

Acamprosate (Campral)

Acamprosate helps restore the chemical balance in the brain that has been disrupted by chronic alcohol use. It is most effective for individuals who have already completed detoxification and are committed to maintaining abstinence. Acamprosate works by reducing the persistent cravings and emotional discomfort that many people experience in early sobriety. It is available by prescription as delayed-release tablets, typically taken three times per day.

Disulfiram (Antabuse)

Disulfiram works through a deterrent mechanism: it causes unpleasant physical reactions, including headache, nausea, vomiting, and flushing, within 10 to 30 minutes of consuming any amount of alcohol. Knowing that drinking will produce these effects serves as a powerful motivator to maintain abstinence. Disulfiram is most effective for highly motivated individuals who have a strong commitment to sobriety.

Naltrexone

Naltrexone, the same medication used to treat opioid use disorder, is also effective for alcohol use disorder. It blocks the rewarding and euphoric effects of alcohol, reducing the desire to drink and helping prevent relapse. For alcohol use disorder, naltrexone is available as daily oral pills or as Vivitrol, a long-lasting monthly injection.

FDA-Approved Medications for Tobacco Use Disorder

Smoking remains one of the leading causes of preventable disease, disability, and death in the United States. Tobacco use disorder is a pattern of compulsive tobacco use that leads to significant distress and health impairment.

FDA-approved smoking cessation medications have been shown to significantly improve quit rates, and combining these medications with behavioral treatment can double a person’s chances of quitting successfully.

Nicotine Replacement Therapy (NRT)

Nicotine replacement therapy helps people stop smoking by providing steady, controlled doses of nicotine that are gradually decreased over time. By satisfying nicotine cravings without the harmful chemicals found in cigarette smoke, NRT eases withdrawal symptoms and helps patients transition away from tobacco. NRT is available in multiple forms, including patches, lozenges, gums, inhalers, and nasal sprays.

Bupropion (Wellbutrin, Zyban)

Bupropion is an antidepressant medication that has been found to reduce cravings and symptoms of nicotine withdrawal. It works on brain chemistry related to dopamine and norepinephrine, helping to ease the mood disturbances and irritability that many people experience when quitting smoking.

Varenicline (Chantix)

Varenicline is a medication specifically designed for smoking cessation. It works by partially stimulating nicotine receptors in the brain, which reduces cravings and makes smoking less pleasurable if a person does smoke while taking it. Varenicline also decreases the discomfort associated with quitting.

Research consistently shows that smokers who receive a combination of cessation medications and behavioral treatment, whether through in-person or phone counseling, quit at significantly higher rates than those who receive minimal intervention.

Addressing Stigma and Misconceptions About MAT

Despite decades of clinical research demonstrating its effectiveness, medication-assisted treatment continues to face significant stigma and misconceptions that can prevent people from seeking the help they need. Addressing these misconceptions directly is important for patients, families, treatment providers, policymakers, and communities.

“MAT Is Just Substituting One Drug for Another”

This is the most common misconception about MAT, and it reflects a fundamental misunderstanding of how these medications work. There is a critical difference between taking a medically supervised, FDA-approved medication at a controlled dosage to treat a diagnosed medical condition and compulsively using an illicit substance that damages your health and life.

MAT medications stabilize brain chemistry, reduce cravings, and block euphoric effects. They do not produce the destructive cycle of intoxication, withdrawal, and compulsive use that defines addiction. Comparing MAT to active substance use is like comparing insulin for diabetes to eating excessive sugar. The medication treats the condition; it does not replicate the disease.

“People on MAT Aren’t Really in Recovery”

Recovery is not defined by the absence of all medication. It is defined by improved health, functioning, and quality of life. People who are stable on MAT, engaged in therapy, rebuilding relationships, maintaining employment, and living fulfilling lives are in recovery by any meaningful standard.

The resistance to accepting MAT as legitimate recovery is rooted in outdated, abstinence-only thinking that does not reflect current medical evidence. Every major medical and addiction organization in the United States, including SAMHSA, the American Society of Addiction Medicine, and the National Institute on Drug Abuse, endorses MAT as a first-line treatment for opioid use disorder.

“MAT Should Only Be Short-Term”

Some individuals do well with short-term MAT, while others benefit from longer-term or even indefinite medication use. The appropriate duration of treatment is a clinical decision that should be based on each patient’s unique circumstances, not on arbitrary timelines or external pressure to “get off the medication.”

Premature discontinuation of MAT medications is one of the most common causes of relapse and overdose. Patient choice, guided by clinical evidence and medical advice, should always be the determining factor in treatment duration.

Stigma in Communities and Healthcare Settings

Stigma around MAT doesn’t only come from the general public. It also exists within some treatment communities, recovery support groups, and even among some healthcare providers. This stigma can discourage patients from starting or continuing MAT, push treatment providers to taper patients too quickly, and create barriers to accessing care.

Combating this stigma requires education, advocacy, and a commitment to evidence-based practice at every level, from individual conversations to institutional policy.

The Importance of Access to MAT

Expanding access to medication-assisted treatment is one of the most important strategies for addressing the opioid epidemic and reducing substance use-related deaths across New York and the United States.

Despite its proven effectiveness, many individuals who could benefit from MAT still cannot access it. Barriers include a shortage of qualified prescribers, limited treatment capacity in many communities, insurance and cost barriers, and the persistent stigma described above.

Recent policy changes have helped improve access. The elimination of the federal X-waiver requirement in 2023 means that any physician with a standard DEA registration can now prescribe buprenorphine for opioid use disorder, significantly expanding the pool of available providers. This change reflects a growing recognition that MAT should be as accessible as treatment for any other chronic medical condition.

Ensuring that all individuals with substance use disorders have access to the full range of evidence-based treatment options, including MAT, is a matter of public health and patient choice. No single approach works for everyone, and expanding treatment capacity means more people can find the path to recovery that works best for them.

Find Medication-Assisted Treatment in New York Today

There is more than one path to recovery from addiction. For many individuals, medication-assisted treatment is a life-saving approach that can help them overcome opioid use disorder, alcohol use disorder, or tobacco use disorder and build a healthy, sustainable life in recovery.

Mid Hudson Addiction Recovery offers comprehensive MAT programs alongside individualized treatment plans that include behavioral therapy, counseling, and wraparound services designed to address every aspect of a patient’s recovery. The center’s experienced medical team works with each patient to determine the most appropriate medications, monitor progress, and adjust treatment as needed.

Reach out to Mid Hudson Addiction Recovery for a confidential assessment. Recovery advocates are available around the clock to help you take the first step toward lasting recovery.

Frequently Asked Questions